Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study

Table 1 Clinical characteristics of the study subjects assigned to the add-on sitagliptin group and continued therapy with conventional antidiabetic agents at baseline

Parameters	Sitagliptin (n = 45)	Conventional (n = 51)	p value
Age	70 ± 8	69 ± 9	0.501
Gender (m/f)	29/16	33/18	0.574
BMI	25.5 ± 3.4	25.5 ± 4.4	0.956
SBP (mmHg)	131 ± 12	130 ± 16	0.643
DBP (mmHg)	74 ± 11	71 ± 12	0.256
HR (beats/min)	67 ± 12	69 ± 11	0.389
Current smoker	3	6	0.412
TC (mmol/L)	4.5 ± 0.8	4.5 ± 0.8	0.879
HDL (mmol/L)	1.3 ± 0.3	1.3 ± 0.4	0.996
TG (mmol/L)	1.5 ± 0.7	1.7 ± 1.0	0.176
Crnn (μmol/L)	76 ± 20	75 ± 21	0.805
eGFR (mL/min per 1.73 m²)	65 ± 16	67 ± 17	0.675
FBG (mmol/L)	6.8 ± 1.6	7.3 ± 1.9	0.560
Hemoglobin A1c (%)	6.9 ± 0.6	7.0 ± 0.6	0.560
Hypertension	38	40	0.313
Dyslipidemia	32	35	0.484
Cerebrovascular disease	5	7	0.471
Cardiovascular disease	23	33	0.127
Medication for diabetes
Insulin	0	0
Biguanides	7	10	0.403
Sulfonylureas	10	11	0.566
Others	21	30	0.162

n number of study subjects, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, brPP brachial pulse pressure, HR heart rate, Current smoker number of current smokers, TC serum total cholesterol, HDL serum high-density lipoprotein cholesterol, TG serum triglyceride, Crnn serum creatinine, eGFR creatinine-based estimated glomerular filtration rate, FBG fasting blood glucose, Hypertension number of subjects with hypertension, Dyslipidemia number of subjects with dyslipidemia, Cerebrovascular disease number of subjects with cerebrovascular disease, Cardiovascular disease number of subjects with cardiovascular disease, Insulin number of subjects treated with insulin, Biguanides number of subjects treated with biguanides, Sulfonylureas number of subjects treated with sulfonylureas, Others number of subjects treated with antidiabetic agents other than insulin, biguanides or sulfonylureas